Kolmar Korea Company Analysis — The No.2 Player I Noticed While Looking at COSMAX
I had recently been analyzing COSMAX and, in the course of looking into the cosmetics ODM industry, naturally ended up checking the DART filings of Kolmar Korea, the industry’s No.2 player. What caught my eye was that Q2 2026 operating profit hit KRW 110.3 billion — the first time in the company’s history it has topped KRW 100 billion in a single quarter, up 50.2% year-over-year. COSMAX still leads on sheer revenue scale, but when it comes to the pace of margin improvement, Kolmar Korea looked like the steeper curve.
This company is a global cosmetics ODM/OEM manufacturer with domestic production bases in Sejong, Incheon, and Bucheon, plus overseas plants spanning the US (two plants in Pennsylvania), China (Beijing and Wuxi), and Canada. In Q2 2026, its cosmetics-segment revenue reached KRW 606.4 billion, overtaking Italy’s Intercos (KRW 465.8 billion) to cement the No.2 spot globally. There are three questions I wanted to answer in this piece. First, what drove the operating margin to nearly double, from 6.3% to 11.9%, in just three years? Second, the debt ratio has fallen for three straight years — is that a coincidence or the result of a deliberate strategy? Third, CAPEX peaked in 2024 and then dropped sharply in H1 2026 — will the new Sejong plant investment push it back up? This analysis is based on Kolmar Korea’s 2026 semi-annual report and its 2023–2025 annual business reports filed with DART.
Kolmar Korea Company Overview — Key Data at a Glance
| Ticker Name | Kolmar Korea | Ticker Code | 161890 (KOSPI) |
| Industry | Cosmetics ODM/OEM (sun care, basic skincare, color cosmetics) — production bases in Korea, the US, China, and Canada | CEO | Hyun-gyu Choi |
| Market Position | World’s No.2 cosmetics ODM (overtook Intercos in Q2 2026) | Listed On | KRX KOSPI |
| H1 2026 Revenue | KRW 1,589.31bn (YoY +14.8%) | Operating Profit | KRW 189.23bn (YoY +41.8%) |
| H1 2026 Operating Margin | 11.9% — improved from 9.6% a year earlier | Net Income (Controlling) | KRW 107.99bn (YoY +124.1%) |
| Q2 2026 (Standalone) Operating Profit | KRW 110.3bn — first time ever topping KRW 100bn in a quarter | Total Assets (H1 2026-end) | KRW 3,628.84bn |
| Total Equity | KRW 1,771.38bn | Debt Ratio | 104.9% — down for three straight years |
| Basis of Analysis | DART 2026 semi-annual report + 2023–2025 annual business reports (consolidated financial statements) | ||
Kolmar Korea Business Structure — How Sun Care Drove the Climb to Global No.2
Kolmar Korea is an ODM/OEM company that develops and manufactures cosmetics on behalf of brand owners. Domestically it runs production bases in Sejong, Incheon, and Bucheon; internationally it operates a global network spanning two plants in Pennsylvania in the US, plants in Beijing and Wuxi in China, and a facility in Canada. Notably, the completion of its second US plant lifted local production capacity from 180 million units to 300 million units — a move the company itself describes as building a “tariff safe zone.” In an export environment where cosmetics face meaningful tariff risk, expanding the share of local production is the company’s central response.
What stood out most in the Q2 2026 results was strength in sun-care products. Riding a broader recovery in K-beauty exports, cosmetics-segment revenue rose to KRW 606.4 billion, overtaking Italy’s Intercos (KRW 465.8 billion) and cementing the No.2 spot globally in cosmetics ODM. COSMAX (KRW 794.9 billion) still holds the No.1 position, but the direction of travel matters more here than the gap itself. That said, the China business isn’t fully in the clear yet. The company is winding down its Beijing plant and consolidating its China operations around the Wuxi plant, but Wuxi’s utilization rate remains weak, and the company is still working to secure enough order volume to hit its production targets there.
Kolmar Korea 3-Year Financial Trend — Operating Margin Up from 6.3% to 11.9%, Debt Ratio Moving the Other Way
| Category | 2023 | 2024 | 2025 | H1 2026 |
|---|---|---|---|---|
| Revenue | KRW 2,155.68bn | KRW 2,452.06bn | KRW 2,722.42bn | KRW 1,589.31bn |
| Operating Profit | KRW 136.14bn | KRW 193.85bn | KRW 239.59bn | KRW 189.23bn |
| Operating Margin | 6.3% | 7.9% | 8.8% | 11.9% |
| Net Income (Controlling) | KRW 5.19bn | KRW 90.07bn | KRW 125.08bn | KRW 107.99bn |
| CAPEX (PP&E Acquisitions) | KRW 106.83bn | KRW 247.17bn | KRW 163.95bn | KRW 36.04bn |
| YoY Operating Profit | — | +42.4% | +23.6% | +41.8% |
| Debt Ratio | 112.1% | 107.7% | 107.4% | 104.9% |
What’s most striking in this table is that the operating margin nearly doubled in three years, from 6.3% in 2023 to 11.9% in H1 2026. Revenue over the same period grew only 1.2x, while operating profit grew nearly 1.4x — meaning this isn’t simply top-line growth, it’s a genuine improvement in profitability. CAPEX is worth watching too. It spiked to KRW 247.17 billion in 2024 on the back of the second US plant’s completion, then plunged to just KRW 36.04 billion in H1 2026. That reads as the tail end of a major investment cycle easing the financial burden — though, as covered below, the new Sejong plant could reverse that trend.
Kolmar Korea In-Depth Balance Sheet Analysis — Debt Ratio Falls, So Why Did Cash Flow Shrink?
| Item | End of 2025 | End of H1 2026 | Change |
|---|---|---|---|
| Total Assets | KRW 3,457.77bn | KRW 3,628.84bn | +4.9% |
| Total Equity | KRW 1,667.35bn | KRW 1,771.38bn | +6.2% |
| Total Liabilities | KRW 1,790.42bn | KRW 1,857.45bn | +3.7% |
| Debt Ratio | 107.4% | 104.9% | -2.5%p |
| Inventory | KRW 324.80bn | KRW 401.11bn | +23.5% |
| Trade Receivables | KRW 333.16bn | KRW 456.75bn | +37.1% |
| Cash and Cash Equivalents | KRW 225.32bn | KRW 176.82bn | -21.5% |
| Operating Cash Flow (H1 2026) | — | KRW 78.61bn | -35.4% vs. KRW 121.69bn a year earlier |
| CAPEX (PP&E Acquisitions, H1 2026) | — | KRW 36.04bn | -63.2% vs. KRW 97.95bn a year earlier |
A debt ratio falling for three straight years is clearly a positive sign — it means total equity, boosted by retained earnings, has been growing faster than liabilities. That said, over the same period inventory rose 23.5% and trade receivables rose 37.1%, and operating cash flow actually fell 35.4% year-over-year. That looks like a case of working-capital pressure building alongside rapid revenue growth. The 21.5% drop in cash and equivalents fits the same story. What stands out, though, is that CAPEX plunged 63.2% year-over-year. With the major investment cycle behind it — the second US plant completed in 2024 chief among them — the company appears to have more room, for now, to direct its cash generation toward strengthening its balance sheet and shareholder returns rather than new investment.
Kolmar Korea CAPEX & New Business — Exiting Beijing, Building the Next Chapter in Sejong
The company is winding down its plant in Beijing and instead investing a total of KRW 173.3 billion to build a new basic-cosmetics manufacturing plant in the Jeonui General Industrial Complex in Sejong, targeting completion by 2028. The weight of this investment is underscored by the fact that Kolmar Korea was the only company the government selected in 2026 for its reshoring (“U-turn”) incentive program. The move reads as consolidating China production around the Wuxi plant while rebuilding domestic production capacity in Korea. That said, with Wuxi’s utilization rate still falling short of target, securing enough Chinese order volume remains a challenge until the new domestic plant comes online.
In the US, the company has already completed its second plant, lifting production capacity from 180 million units to 300 million units. The company itself frames this as building a “tariff safe zone” — expanding the share of US-based production has become a core lever for managing trade-policy risk. It’s also worth noting that the company has been placing global talent on the front lines to push harder into the North American market. Taken together, Kolmar Korea’s CAPEX cycle appears to be moving in sequence — the US (tariff response), then China (restructuring), and now Korea (the new plant) — which suggests that once the Sejong investment ramps up in earnest, the recently sharp CAPEX decline is likely to reverse.
Kolmar Korea — Why the Operating Margin Nearly Doubled
| Cause | Details | Temporary / Structural |
|---|---|---|
| ① A Sun-Care-Led K-Beauty Export Tailwind | Strength in sun-care products drove Q2 operating profit past KRW 100 billion for the first time ever (up 50.2% YoY), while cosmetics-segment revenue widened the gap in the No.2 global spot | Structural (broad-based growth across the K-beauty industry) |
| ② A Normalizing CAPEX Cycle | With major investments like the second US plant (completed 2024) behind it, H1 2026 CAPEX fell 63.2% year-over-year, freeing up more room for cash generation | Partly temporary (could reverse once the Sejong plant investment ramps up) |
| ③ An Improving Balance Sheet | The debt ratio has fallen from 112.1% in 2023 to 104.9% at the end of H1 2026 for three straight years, supported by equity growth from retained earnings | Structural (a direct result of improving profitability) |
✅ 3 Investment Highlights
① First-Ever KRW 100bn+ Quarterly Operating Profit, Rising to No.2 in Global ODM
Q2 2026 operating profit of KRW 110.3 billion marked the company’s first time ever crossing the KRW 100 billion mark in a single quarter, while its cosmetics revenue widened the gap over Intercos to secure the No.2 global spot.
② Debt Ratio Down for Three Straight Years
From 112.1% in 2023 to 104.9% at the end of H1 2026, the company’s financial health has been improving right alongside its revenue growth.
③ US Plant Completion Plus a New Sejong Plant Rebuild the Growth Base
US production capacity has already been expanded to 300 million units to get ahead of tariff risk, while a new KRW 173.3 billion plant in Sejong is set to strengthen domestic production capacity as well.
⚠️ 3 Risks
① Weak Utilization at the Wuxi Plant in China
Having consolidated China production around Wuxi after winding down Beijing, the company is still struggling to secure enough order volume to hit its production targets there.
② Governance Uncertainty From the Founding Family
The Kolmar group went through a family ownership dispute that has only recently settled. While currently resolved, further shifts in holding-company and affiliate governance remain a variable worth watching.
③ Slower Cash Flow From Rising Receivables and Inventory
Inventory and trade receivables rose 23.5% and 37.1% respectively, while operating cash flow fell 35.4% year-over-year. Whether this is simply a normal consequence of revenue growth needs to keep being confirmed.
My Investment Judgment After Analyzing Kolmar Korea
What struck me most after digging into this company is that profitability and balance-sheet health are improving at the same time. The operating margin has nearly doubled in three years, while the debt ratio has fallen steadily over the same period. Slower cash flow from rising receivables and inventory, and weak utilization at the Wuxi plant in China, remain unfinished business — but the expansion of US production capacity and the new Sejong plant investment show a company clearly preparing its next growth phase.
My judgment is to increase my position (buying in tranches). There are two key reasons behind that. First, crossing KRW 100 billion in quarterly operating profit for the first time while cementing the No.2 spot in global cosmetics ODM doesn’t look like a one-off — it looks like a structural shift rooted in genuine product competitiveness, sun care chief among them. Second, with the debt ratio falling for three straight years, the balance sheet is building the capacity to absorb the next CAPEX up-cycle when it comes. That said, the utilization rate at Wuxi and the governance overhang are variables I’ll keep confirming.
Here are the triggers that would change my judgment: ① confirmation that Wuxi’s utilization rate is improving and that China is starting to contribute to profit, and ② the Sejong plant investment ramping up in a way that drives CAPEX and borrowing back up sharply enough to reverse the recent improvement in the debt ratio. If clear signs of the latter emerge, I will stop adding to my position and move to a wait-and-see stance.
⚠️ Investment Disclaimer
This article is an individual investor’s analysis based on DART electronic disclosure filings and does not constitute investment advice.
All investment decisions must be made based on your own judgment and at your own responsibility.
Investing in stocks carries the risk of loss of principal.
References
- DART Electronic Disclosure System: https://dart.fss.or.kr
- Kolmar Korea official website: https://www.kolmar.co.kr
- Kolmar Korea Q2 operating profit KRW 110.3bn, first time topping KRW 100bn in a quarter (Ajunews): https://www.ajunews.com/view/20260812170209563
- Kolmar Korea’s Wuxi plant utilization rate in China remains weak (Businesspost): https://www.businesspost.co.kr/BP?command=article_view&num=444219
- Basis of analysis: DART 2026 semi-annual report + 2023–2025 annual business reports (consolidated financial statements)
